Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1
Issued Date
2024-09-01
Resource Type
ISSN
00426822
eISSN
10960341
Scopus ID
2-s2.0-85196824030
Journal Title
Virology
Volume
597
Rights Holder(s)
SCOPUS
Bibliographic Citation
Virology Vol.597 (2024)
Suggested Citation
Kim J., Villar Z., Jobe O., Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., O'Connell R.J., Ake J.A., Vasan S., Rao V.B., Rao M. Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1. Virology Vol.597 (2024). doi:10.1016/j.virol.2024.110158 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/99256
Title
Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1
Corresponding Author(s)
Other Contributor(s)
Abstract
An important approach to stopping the AIDS epidemic is the development of a vaccine that elicits antibodies that block virus capture, the initial interactions of HIV-1 with the target cells, and replication. We utilized a previously developed qRT-PCR-based assay to examine the effects of broadly neutralizing antibodies (bNAbs), plasma from vaccine trials, and monoclonal antibodies (mAbs) on virus capture and replication. A panel of bNAbs inhibited primary HIV-1 replication in PBMCs but not virus capture. Plasma from RV144 and RV305 trial vaccinees demonstrated inhibition of virus capture with the HIV-1 subtype prevalent in Thailand. Several RV305 derived V2-specific mAbs inhibited virus replication. One of these RV305 derived V2-specific mAbs inhibited both virus capture and replication, demonstrating that it is possible to elicit antibodies by vaccination that inhibit virus capture and replication. Induction of a combination of such antibodies may be the key to protection from HIV-1 acquisition.